With combined sales from the top HIV treatment on the market, Atripla, and several other drugs, Gilead Sciences leads the antiviral market, closely followed by Bristol-Myers Squibb, Roche and Merck & Co.
That is the key point in a report from Kalorama Information, the healthcare market research firm, which notes that the market for all anti-infectives reached $53 billion in 2011. It points out that Atripla (efavirenz/tenofovir/emtricitabine) is expected to bring in $3.2 billion in sales in 2011 and the HIV drugs Truvada (emtricitabine/tenofovir) and Viread (tenofovir), plus the hepatitis B drug Hepsera (adefovir) are performing well.
However, in a highly competitive market, other companies are gaining, the analysis notes. B-MS is second, driven by its nucleoside analogue Baraclude (entecavir) for hepatitis B; its sales have grown from $257 million in 2007 to $1.1 billion now. As for the firm's HIV drugs, the Sustiva (efavirenz) franchise and Reyataz (atazanavir) are growing steadily.
Roche holds the third market position overall, helped by Pegasys (peginterferon alfa-2a), for hepatitis B and C, the transplantation product Valcyte (valganciclovir) and the influenza jab Tamiflu (oseltamivir). At the end of last year, the Swiss major announced plans to acquire the USA's Anadys Pharmaceuticals, a hepatitis C specialist, for around $230 million.
Kalorama notes that GlaxoSmithKline alone accounted for 25% of the antiviral market in 2009, but has since declined due to patent expirations. on key products. However its HIV joint venture with Pfizer, ViiV Healthcare, accounted for one-tenth of the antiviral drug market in 2011.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.